Implitapide

Drug Profile

Implitapide

Alternative Names: AEGR 427 implitapide; AEGR-427; BAY 13-9952

Latest Information Update: 30 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Class Antihyperlipidaemics; Indoles; Pyridines
  • Mechanism of Action Microsomal triglyceride transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type II
  • New Molecular Entity No

Highest Development Phases

  • Suspended Hypercholesterolaemia
  • Discontinued Hyperlipidaemia; Hyperlipoproteinaemia type II; Hypertriglyceridaemia

Most Recent Events

  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
  • 31 Dec 2011 Suspended - Phase-II for Hypercholesterolaemia in USA (PO)
  • 07 Feb 2007 Phase-II clinical trials in Hypercholesterolaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top